Newsletter

June 2018 Scorecard

The June 2018 scorecard for the signals generated from Rocket Tickers can be downloaded here. For more information regarding how you can trade these signals, see the article Trading Clinical Trials Try Rocket Tickers 30 days for free and cancel anytime! Subscribe here and check out the Training Webinar

0Comments

Zafgen Reports Positive Phase 2 Clinical Trial Results for ZGN-1061

On June 23, Zafgen, Inc. (ZFGN) reported positive results from the company’s Phase 2 clinical trial of ZGN-1061. The trial is designed to prove the drug’s efficacy and safety in patients with type 2 diabetes and to establish a minimally effective dose. Zafgen reported that the patients had no treatment-related serious adverse events.   Rocket Tickers […]

0Comments

Global Blood Therapeutics Reports Positive Phase 3 HOPE Study Results

Global Blood Therapeutics, Inc. (GBT) announced its positive top-line Phase 3 clinical trial data on June 27. The results are from Part A of the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymEmerization) Study to evaluate the use of voxelotor as a treatment for sickle cell disease. On the primary endpoint, patients […]

0Comments

Ironwood Pharmaceuticals Receives FDA Orphan Drug Designation for Olinciguat

Ironwood Pharmaceuticals Inc. (IRWD) announced on June 7 that the FDA granted Orphan Drug Designation to Olinciguat (IW-1701) for patients with sickle cell disease. The FDA grants orphan status to drugs that are intended to treat rare disorders that affect fewer than 200,000 patients in the United States. The designation gives the developer fee waivers and […]

0Comments

May 2018 Scorecard

The May 2018 scorecard for the signals generated from Rocket Tickers can be downloaded here. For more information regarding how you can trade these signals, see the article Trading Clinical Trials Try Rocket Tickers 30 days for free and cancel anytime! Subscribe here and check out the Training Webinar

0Comments

Published Study Supports Global Medical’s Expandable Lateral Technology

On May 15, Global Medical, Inc. (GMED) reported the results of a medical study that supported the benefits of the company’s Globus expandable lateral spacers. The study “Clinical and radiographic analysis of expandable versus static lateral lumbar interbody fusion devices with two-year follow-up” was published in the Journal of Spine Surgery. Dr. Joseph O’Brien, MD, […]

0Comments

Avinger Receives FDA Clearance for Patheris Lumivascular Artherectomy System

Avinger, Inc. reported on May 23 that the company has received 510(k) clearance from the FDA for its next-generation Pantheris Lumivascular atherectomy system. Lumivascular is the only technology that combines both real-time intravascular imaging with catheters to treat peripheral artery disease (PAD). This is the first image-guided atherectomy device for the treatment of PAD. Rocket […]

0Comments

Lannett Receives FDA Approval for Dronabinol Capsules

Lannett Company, Inc. (LCI) announced on May 21 that they have received FDA approval for Dronabinol Capsules. The drug is the therapeutic equivalent to Marinol Capsules, and only a handful of suppliers manufacture generic versions of the drug for the US market. Dronabinol Capsules can be used to treat patients with loss of appetite due […]

0Comments

RXi Reports Positive Phase 2 Clinical Trial Results for Treatment of Common Warts

On May 18, RXi Pharmaceuticals Corporation (RXII) reported positive results from its phase 2 clinical trial of the drug Samcyprone for the treatment of common warts. After weekly application for 10 weeks, participants had a 97.7% positive immunotherapy response rate. 70% of participants experienced a reduction of at least 50% wart size. There is currently […]

0Comments

Karypharm Reports Positive Results From Phase 2b Clinical Trial of Selinexor

On April 30, Karyopharm Therapeutics, Inc. (KPTI) announced positive results from its phase 2b STORM study examining the effect of Selinexor in patients with penta-refractory multiple myeloma. The clinical trial showed that patients had a 25.4% overall response rate to the treatment. Based on the results, Karyopharm plans to submit a New Drug Application to […]

0Comments

Latest of Knowledge Center